Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy
Journal Title
Cell Reports Medicine
Publication Type
Online publication before print
Abstract
Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions. Here, we combine time course RNA sequencing (RNA-seq) of peripheral blood mononuclear cells with pre-treatment tumor transcriptome data from the single-arm, phase 2 DREAM trial (N = 54). Single-cell RNA-seq and T cell receptor sequencing (TCR-seq) reveal that CD8(+) T effector memory (TEM) cells with stem-like properties are more abundant in peripheral blood of responders and that this population expands upon treatment. These peripheral blood changes are linked to the transcriptional state of the tumor microenvironment. Combining information from both compartments, rather than individually, is most predictive of response. Our study highlights complex interactions between the tumor and immune cells in peripheral blood during objective tumor responses to chemoimmunotherapy. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12616001170415.
Keywords
CD8(+) T effector memory cells; Ict; Pd-l1; biomarkers; cancer; immune checkpoint therapy; mesothelioma; peripheral blood; platinum chemotherapy; response; single-cell RNA sequencing
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1016/j.xcrm.2024.101882
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-01-14 06:32:55
Last Modified: 2025-01-14 06:38:14

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙